Zealand Pharma
Company Information
Zealand Pharma is a biotechnology company that offers scientific expertise in turning peptides into medicines.
Industries: | Biotechnology Pharmaceuticals and Life Sciences Health Care | |
---|---|---|
Locations: | Marlborough Boston Copenhagen Glostrup New York, Ny Søborg | |
crunchbase: | https://www.crunchbase.com/organization/zealand-pharma | |
twitter: | http://www.twitter.com/zealandpharma | |
linkedin: | https://www.linkedin.com/company/zealand-pharma | |
homepage: | https://zealandpharma.com | |
info@zealandpharma.com | ||
Description: | Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (“Zealand”) is a biotech company with leading-edge scientific expertise in turning peptides into medicines. Zealand has a growing proprietary pipeline of novel specialty drug candidates and a mature portfolio of products and projects under license collaborations with Sanofi, Helsinn Healthcare and Boehringer Ingelheim.
Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of Type 2 diabetes, is marketed globally outside the US as Lyxumia:registered: by Sanofi and under regulatory review in the US. The license collaboration with Sanofi covers also a single-product combination of lixisenatide and insulin glargine (Lantus:registered:) which is on track for regulatory submission in the US in December 2015 and in the European Union in Q1 2016.
The proprietary pipeline includes; danegaptide for ischemic reperfusion Injuries in Phase II development; ZP1848 for Short Bowel Syndrome in Phase II development; and the stable glucagon analogue, ZP4207, in Phase II preparation both as a single-dose rescue pen for severe hypoglycemia and for multiple-dose use to treat and control mild to moderate hypoglycemia; as well as several preclinical peptide therapeutics.
The company is based in Copenhagen (Glostrup), Denmark. For further information about Zealand’s business and activities, please visit: www.zealandpharma.com or follow us on Twitter @ZealandPharma | |
Stock Code: | NASDAQ:ZEAL |
Employees
201-500
Trends
Last 4 weeks
Last 3 months
DivestingInvesting
Recent Events
News
Job Posting
Other News
See All news